Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy (ATARI)

  • End date
    Mar 27, 2024
  • participants needed
  • sponsor
    Philippe Bégin
Updated on 27 May 2022


This is a phase 2a, multi-center, randomized and double-blind placebo-controlled trial comparing 24 weeks of abatacept versus placebo used as adjuvant to oral immunotherapy to induce remission in adolescents and adults with persistent severe peanut allergy.

This is a proof-of-concept trial in which the primary outcome will be the suppression of the initial peanut specific IgE surge during OIT, which is used as a proxy outcome of peanut allergy remission.

Adolescents and adults with persistent severe peanut allergy (n=14) will be randomized to either abatacept or placebo at a ratio 1:1 for a total period of 24 weeks. Peanut oral immunotherapy will be initiated the day following the first administration of the investigational product. Sustained tolerance to peanut will be assessed at 36 weeks.

Condition Peanut Allergy
Treatment Placebo, Abatacept, Peanut Oral Immunotherapy
Clinical Study IdentifierNCT04872218
SponsorPhilippe Bégin
Last Modified on27 May 2022


Yes No Not Sure

Inclusion Criteria

Male or female subjects 14 to 50 years old at screening visit
History of IgE mediated allergy to peanut protein
ImmunoCAP IgE level > 50 kU/L for peanut
Total IgE level < 5000 kU/L
Willing to comply to all study requirements during participation in the study

Exclusion Criteria

Previous adverse reactions to abatacept
Known hypersensitivity to abatacept or any of its components
Patients at risk of sepsis, such as immunocompromised or HIV positive
Patient undergoing a treatment with any other biologic agent
Uncontrolled asthma
Unstable angina, significant arrhythmia, uncontrolled hypertension, chronic sinusitis, or other chronic or immunological diseases that, in the judgment of the investigator, might interfere with the evaluation, administration of the test drug or pose additional risk to the subject (e.g., gastrointestinal or gastroesophageal disease, chronic infections, scleroderma, hepatic and gallbladder disease, chronic non-allergic pulmonary disease)
Current users of oral, intramuscular, or intravenous corticosteroids, tricyclic antidepressants or beta-blocker
Concurrent/prior use of immunomodulatory therapy (within 6 months)
A diagnosis of eosinophilic esophagitis, eosinophilic colitis, or eosinophilic gastritis
Pregnant or breastfeeding women
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note